CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) Research Peptide: A Synergistic Tool for GH & Cardioprotection Studies

If your research investigates the dual pathways of growth hormone (GH) secretion and cardioprotective signalling, the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide offers a precisely defined, dual‑pathway experimental platform. This 10 mg formulation combines CJC‑1295 (Modified GRF 1‑29), a stabilised GHRH analogue, with Hexarelin, a potent ghrelin receptor agonist. By targeting two distinct yet complementary receptors, this blend allows researchers to model the synergistic interplay between sustained GHRH stimulation and high‑amplitude GH pulses, all while leveraging Hexarelin’s unique GH‑independent cardioprotective properties. This makes the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide a valuable tool for laboratories investigating endocrine signalling, metabolic regulation, and cardiac protection.

At Chinese Grey Peptides, we supply high‑purity CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥99% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation and cardioprotection begin with uncompromising quality.

What Is the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) and How Does It Work?

To fully appreciate the research potential of the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide, it is essential to understand the distinct yet complementary mechanisms of its two components.

CJC‑1295 (Mod GRF 1‑29): The Stabilised GHRH Analogue

CJC‑1295 (Mod GRF 1‑29), also referred to as CJC‑1295 without DAC, is a modified analogue of growth hormone‑releasing hormone (GHRH). It is a 29‑amino‑acid peptide with four amino acid substitutions that enhance its activity and render it resistant to proteolytic degradation by enzymes such as dipeptidyl peptidase‑IV. Unlike CJC‑1295‑DAC, which contains a drug affinity complex and has a half‑life of approximately 8 days, Mod GRF 1‑29 does not contain the DAC moiety and has a shorter half‑life of approximately 30 minutes.

As a GHRH analogue, CJC‑1295 binds to GHRH receptors on anterior pituitary somatotrophs, driving cAMP/PKA‑mediated GH synthesis and secretion. The version without DAC creates short, sharp GH pulses that closely mimic natural physiology, making it ideal for studying acute GH signalling and metabolic regulation.

Hexarelin: The Potent Ghrelin Receptor Agonist

Hexarelin (Examorelin) is a synthetic hexapeptide belonging to the growth hormone‑releasing peptide (GHRP) class. Its sequence is His‑D‑2‑methyl‑Trp‑Ala‑Trp‑D‑Phe‑Lys‑NH₂. It acts via specific receptors at both the pituitary and hypothalamic levels to stimulate GH release.

Hexarelin engages the GHS‑R1a receptor through Gq/11‑coupled signalling, mobilising intracellular calcium to trigger GH granule release. Critically, Hexarelin also binds the scavenger receptor CD36, which mediates many of its GH‑independent cardioprotective effects including anti‑atherosclerotic and anti‑ischaemic activity. This distinct cardiac tropism makes Hexarelin unique among GHRPs for research applications involving cardiovascular protection.

Mechanism of Synergy: Complementary Pathways

The scientific rationale for combining CJC‑1295 and Hexarelin lies in their convergent yet distinct mechanisms. When conceptualised as a blended research framework, these peptides invite investigation into how their complementary properties might interact:

• CJC‑1295 (Mod GRF 1‑29) provides sustained GHRH‑receptor engagement via the cAMP/PKA pathway, supporting physiological GH pulsatility.

• Hexarelin amplifies the response by engaging the GHS‑R1a receptor through calcium‑mediated signalling, while its CD36 binding provides direct cardiac myocyte protection.

• Somatostatin Suppression: Hexarelin also suppresses hypothalamic somatostatin, removing the brake on GH release.

This dual‑pathway activation has been shown to produce synergistic GH release that is 2‑3 fold higher than either peptide alone. The combination of CJC‑1295 and Hexarelin is hypothesised to produce maximum GH secretion with cardioprotective effects. Hexarelin stacking with a GHRH analogue like CJC‑1295 is considered a classic GHRP + GHRH stack structure for synergistic GH pulse amplification.

Key Research Applications for the CJC‑1295 (Mod GRF 1‑29) & Hexarelin Blend

The CJC‑1295 (Mod GRF 1‑29) & Hexarelin Blend (10mg) research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Growth Hormone Axis & Pituitary Function Studies

This blend provides a powerful model for investigating the hypothalamic‑pituitary‑somatotropic axis. Researchers can use it to study:

• The synergistic effects of GHRH and ghrelin pathway co‑activation on GH synthesis, storage, and pulsatile release.

• The distinct contributions of GHRH‑mediated and ghrelin‑mediated signalling to overall GH secretion.

• The dynamics of GH pulse amplitude and frequency in response to dual‑pathway stimulation.

• Neuroendocrine rhythms and receptor dynamics.

2. Cardioprotective & Cardiovascular Research

Hexarelin’s unique CD36‑mediated cardioprotective effects make this blend a valuable tool for cardiovascular research. Research applications include:

• GH‑Independent Cardioprotection: Investigating Hexarelin’s direct cardiac myocyte protection, anti‑inflammatory signalling, and lipid metabolism modulation.

• Cardiac Function Studies: Researchers have reported that Hexarelin can increase left ventricular ejection fraction.

• Ischaemic Models: Exploring Hexarelin’s anti‑ischaemic activity.

• Anti‑Atherosclerotic Research: Investigating the peptide’s role in atherosclerosis models.

3. Metabolic & Body Composition Research

By stimulating endogenous GH release through two pathways, this blend provides a model for studying the downstream metabolic effects of GH and IGF‑1 elevation. Research applications include:

• Lean Body Mass: Pulsatile GH administration has been shown to be more effective than continuous infusion for promoting lean body mass and reducing adiposity.

• Anti‑Cachectic Effects: Hexarelin has demonstrated anti‑cachectic effects independent of GH release, preserving skeletal muscle mitochondrial function and calcium homeostasis during catabolic states.

• Lipolysis and Protein Synthesis: Research suggests the high‑amplitude pulses produced by this blend maximise acute IGF‑1 production from hepatocytes, stimulating protein synthesis and lipolysis.

4. Receptor Pharmacology & Signalling Research

As a combination of two mechanistically distinct receptor agonists, this blend serves as a molecular probe for studying receptor pharmacology:

• GHRH Receptor Signalling: Investigating the cAMP/PKA pathway activated by CJC‑1295.

• GHS‑R1a Signalling: Studying the Gq/11‑coupled calcium mobilisation pathway triggered by Hexarelin.

• CD36 Receptor Research: Exploring Hexarelin’s binding to the scavenger receptor CD36 and its downstream effects.

• Receptor Cross‑Talk: Characterising how simultaneous activation of both receptor types may initiate synergistic actions.

5. Recovery & Tissue Repair Research

The blend’s ability to maximise GH pulse amplitude and provide GH‑independent muscle‑protective effects positions it as a valuable tool for recovery research:

• Muscle Recovery Models: Investigating the combined anabolic signalling and muscle‑protective effects.

• Collagen Synthesis: Studying the effects of elevated GH on collagen synthesis and tissue repair.

• Catabolic State Models: Exploring Hexarelin’s anti‑cachectic effects in preserving muscle function during catabolic states.

Chemical & Physical Specifications for CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Accurate characterisation of the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide is essential for reproducible experimental design.

Note: The 10 mg mass represents the total peptide weight of the blend (5 mg CJC‑1295 (Mod GRF 1‑29) + 5 mg Hexarelin). The blend is supplied in a single lyophilised vial. CJC‑1295 in this blend does not contain the Drug Affinity Complex (DAC) moiety, preserving physiological pulsatility. This product is intended strictly for in‑vitro and laboratory research use only (RUO). Not for human or animal use.

Reconstitution & Handling Protocol for the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Proper reconstitution of the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide is critical for maintaining the structural integrity and biological activity of both peptides.

Step 1 – Preparation

• Bring the sealed blend vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the blend vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 10 mg per 1‑2 mL of diluent, yielding a 5‑10 mg/mL total peptide concentration.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted peptide blend into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles.

• Once thawed, store at 2‑8°C and use within 14‑21 days.

Concentration Reference Table for CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Adjust diluent volume based on your experimental requirements. The exact concentration of each individual peptide within the blend is 5 mg CJC‑1295 (Mod GRF 1‑29) and 5 mg Hexarelin per 10 mg vial.

Storage & Stability Guidelines for CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Why Choose Chinese Grey Peptides for the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)?

As an authentic licensed peptide supplier based in the USA, we supply the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥99% for each component, every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO). This peptide blend is intended strictly for laboratory research, analytical, or reference use, where permitted by local regulations. Not for human or veterinary use.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

 What is the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide?
It is a research‑grade formulation combining CJC‑1295 (Mod GRF 1‑29, a modified GHRH analogue without DAC) and Hexarelin (a potent ghrelin receptor agonist). It is used as a dual‑pathway tool to study growth hormone stimulation, cardioprotection, and metabolic research.

 How does each component work?
CJC‑1295 (Mod GRF 1‑29) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release via the cAMP/PKA pathway. Hexarelin binds to the growth hormone secretagogue receptor (GHS‑R1a), amplifying GH release via calcium mobilisation, while also binding CD36 for GH‑independent cardioprotective effects.

What is the proposed synergy between CJC‑1295 and Hexarelin?
CJC‑1295 provides sustained GHRH‑receptor engagement and physiological GH pulsatility, while Hexarelin amplifies the response through the ghrelin receptor axis and suppresses somatostatin. GHRH + GHRP co‑administration produces GH peaks 2‑3 fold higher than either peptide alone.

What makes Hexarelin unique among GHRPs in research?
Hexarelin exhibits strong cardioprotective activity independent of its GH‑releasing effects through binding to the CD36 receptor. This provides direct cardiac myocyte protection, anti‑inflammatory signalling, and lipid metabolism modulation.

 What purity does your CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) meet?
Each component is tested to ≥99% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute this peptide blend?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

How should I store reconstituted peptide blends?
Reconstituted blends should be stored at 2‑8°C and used within 14‑21 days. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

 Is this peptide blend legal to purchase in the USA for research?
Yes. This blend is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: CJC‑1295 and Hexarelin are not FDA‑approved for therapeutic use and are prohibited by the World Anti‑Doping Agency (WADA) for athletic use.

What is the difference between CJC‑1295 with DAC and without DAC?
CJC‑1295 without DAC (Mod GRF 1‑29) has a half‑life of approximately 30 minutes and supports a pulsatile release pattern that mimics natural physiology. CJC‑1295 with DAC has a half‑life of approximately 8 days and produces sustained continuous GH elevation.

 Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubChem CJC-1295
• PubChem Examorelin / Hexarelin
• FDA compounding-risk page for CJC-1295
• WADA Growth Hormone Releasing Factors Testing Guide
• FDA Gram Peptides warning letter
• Google Merchant Listing Structured Data
• Rank Math WooCommerce Product Schema

CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

Important Compliance Notice

CJC-1295 Hexarelin Blend 10mg may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, growth hormone claims, anti-aging claims, fat-loss claims, muscle-growth claims, recovery claims, athletic-performance claims, bodybuilding claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, sport-governing rules, labeling rules, and permitted-use requirements before ordering.

From its innovative design as a dual‑pathway GH secretagogue blend to its well‑documented role in modelling the synergistic interplay between the GHRH and ghrelin systems, the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide provides a uniquely versatile platform for advanced endocrinological, metabolic, and cardiovascular research.

CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

Its ability to stimulate endogenous GH release through two distinct yet convergent pathways—CJC‑1295 providing sustained GHRH‑receptor engagement and Hexarelin amplifying through the ghrelin receptor axis while offering GH‑independent cardioprotection—supported by research demonstrating synergistic GH release and Hexarelin’s unique CD36‑mediated cardiac effects, makes it a valuable addition to any laboratory investigating the GH/IGF‑1 axis, metabolic regulation, or cardioprotection. By choosing high‑purity, lab‑verified CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg) research peptide from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with the CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade research peptides delivered directly to your facility in the USA, UK, or Europe.CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)

CJC-1295 (Mod GRF 1-29) & Hexarelin Blend (10mg)